Anti-CD3 monoclonal antibody ior ch-t3

Drug Profile

Anti-CD3 monoclonal antibody ior ch-t3

Alternative Names: Chimaeric ior t3 monoclonal antibody; Ior ch-t3 anti-CD3 monoclonal antibody

Latest Information Update: 02 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center of Molecular Immunology
  • Developer CIMAB
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 07 Mar 2003 Preclinical trials in Transplant rejection in Cuba (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top